Similarly, in the TREAT trial involving T2DM patients having anaemia and predialysis chronic kidney disease, the incorporation of NT-proBNP along with troponin T demonstrated a substantial enhancement of 17.8% in predicting cardiovascular outcomes [47]. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.